SCHEMBL7201570

SCHEMBL7201570

C=CCOP(=O)(NC(C=C)CC(=O)OCC)c1ccc(OCC(C)C)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.38
HTT P42858 2/20 0.38
LMNA P02545 2/20 0.38
MMP1 P03956 1/20 0.38
MMP3 P08254 1/20 0.38
MMP9 P14780 1/20 0.38
GAA P10253 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.35
MAPT P10636 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
POLB P06746 1/20 0.35
CYP2D6 P10635 1/20 0.34
SMPD1 P17405 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
ADRB2 P07550 1/20 0.32
ADRB1 P08588 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6545932 0.71 LMNA (0.43) HTTLMNAGAASMN1; SMN2MAPT
SCHEMBL6545462 0.70 NPSR1 (0.40) HTTLMNAGAANPSR1SMN1; SMN2
SCHEMBL8417819 0.67 SMN1; SMN2 (0.47) HTTGAANPSR1SMN1; SMN2MAPT
SCHEMBL31488094 0.65 MAPT (0.53) HTTGAANPSR1SMN1; SMN2MAPT
SCHEMBL7223729 0.63 MAOB (0.43) LMNAGAANPSR1SMN1; SMN2MAPT
SCHEMBL8421528 0.62 SMN1; SMN2 (0.61) LMNAGAANPSR1SMN1; SMN2MAPT
SCHEMBL6545061 0.62 MAPT (0.49) GAASMN1; SMN2MAPTNPC1RAB9A
SCHEMBL6545935 0.61 GAA (0.39) HTTLMNAGAASMN1; SMN2MAPT
SCHEMBL948679 0.61 KMT2A (0.58) LMNAGAANPSR1MAPTKMT2A
SCHEMBL6448296 0.60 MAPT (0.50) GAANPSR1SMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6605742-B2 Rheumatic diseases; antiarthritic agents; antitumor agents LEO PHARMA A/S (DK) 2003-08-12 US disclosed
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons LEO PHARMA A/S (DK) 2002-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons CMA1, MMP9, CPA1 ADAM17 10/4885HTT 4549/4885LMNA 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.